Stocks Health care MTEX
NASDAQ · Health careMannatech Inc (MTEX)
Mannatech Inc brought in $107.4M of revenue over the twelve months to June 30, 2026, down 5.0% from a year earlier. It posted a net loss of $7.4M. In fiscal 2025 capital spending exceeded operating cash flow by $4.3M. At June 30, 2026 it held $6M in cash against $2.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Watch MTEX in 60 secondsWhat Mannatech Inc does
Mannatech Inc is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NASDAQ under the ticker MTEX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $108M | -$15.2M | -$8.00 | -$4.3M |
| 2024 | $117.9M | $2.5M | $1.32 | $2M |
| 2023 | $132M | -$2.2M | -$1.20 | -$3.1M |
| 2022 | $137.2M | -$4.5M | -$2.35 | -$3.7M |
| 2021 | $159.8M | $9.8M | $4.71 | $10.1M |
| 2020 | $151.4M | $6.3M | $2.77 | $5.1M |
Full financial statements: income, balance sheet and cash flow
Where MTEX ranks in Health care
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2024 | n/a | $0 | 0% |
| 2023 | $0.20 | $748K | n/a |
| 2022 | n/a | $1.5M | n/a |
| 2021 | n/a | $4.3M | 44% |
| 2020 | n/a | $3.4M | 54% |
| 2019 | n/a | $1.2M | 36% |
Latest SEC filings
What Mannatech Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026
- August 19, 2026Passive stake changed SCHEDULE 13G/A
- August 19, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 3.8% to $26.7M versus the same quarter last year; diluted EPS $0.53 versus -$2.27.
- June 8, 2026
- June 3, 2026
- May 14, 2026
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 6.2% to $24.9M versus the same quarter last year; diluted EPS $0.49 versus -$0.80.
- April 24, 2026
Insider trades
What the people running Mannatech Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 20, 2026 | Jobe Larry ADirector | Bought | 2,803 | $11.5K |
| May 19, 2026 | Robbins Kevin AndrewDirector | Bought | 7,100 | $29.6K |
| May 19, 2026 | Jobe Larry ADirector | Bought | 5,000 | $21K |
Who owns MTEX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lacore Terry13G, passive | 8.3% | August 19, 2026 |
| Toth Robert13D, may seek influence | 5.1% | April 24, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 103,333 shares in total, about $795.7K at the last price.
| Holder | Shares |
|---|---|
| Jobe Larry ADirector | 70,000 |
| Robbins Kevin AndrewDirector | 33,333 |
Questions about MTEX
What does Mannatech Inc do?
Mannatech Inc is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NASDAQ under the ticker MTEX.
Is Mannatech Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $7.4M on revenue of $107.4M.
How much revenue does Mannatech Inc make?
Over the twelve months to June 30, 2026 Mannatech Inc reported revenue of $107.4M. That is 5.0% less than a year earlier.
When did Mannatech Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 1, 2026.
Similar companies
Compare MTEX with
Follow MTEX
Get an email when Mannatech Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow MTEX: get an email when it filesWhere the numbers come from
Financial figures are the values Mannatech Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.